78 results
Page 4 of 4
8-K
EX-1.2
go76gv6 4c
21 Feb 19
Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock
4:53pm
424B5
qgynsy
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
pijt4ba2j tl9
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
0bgtnt0
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
EX-99.2
s7b1utughakcrlwkb
17 Dec 18
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
8:05am
8-K
EX-99.1
7xd9kw0pee9z6sy0zn4m
6 Dec 18
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
8:05am
8-K
EX-99.1
rcgiwewrse180s9tx4cr
8 Nov 18
Ovid Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Recent Clinical Progress
7:40am
8-K
EX-99.1
k0c1m2l6
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.1
ih9g01ifxn09t4h25
1 Oct 18
Regulation FD Disclosure
12:00am
8-K
EX-99.1
r1utq8n8aw2f
6 Aug 18
Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome
7:16am
8-K
EX-99.1
b8cqu
19 Jul 18
Other Events
6:59am
S-3
0b33iay 1xwaec
1 Jun 18
Shelf registration
5:14pm
10-K
37jxz xpmx
29 Mar 18
Annual report
12:00am